High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

Bone Marrow Transplantation

Volumn 46, Issue 8, 2011, Pages 1104-1112

  Hoegh Petersen, M ^a   Goodyear, D ^a   Geddes, M N ^a   Liu, S ^a   Ugarte Torres, A ^a   Liu, Y ^a   Walker, J T ^a   Fonseca, K ^a   Daly, A ^a   Duggan, P ^a   Stewart, D ^a   Russell, J A ^a   Storek, J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

antithymocyte globulin; EBV; hematopoietic cell transplantation; post transplant lymphoproliferative disorder

Indexed keywords

BUSULFAN; CYCLOSPORIN; FLUDARABINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; METHOTREXATE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BIOPSY TECHNIQUE; CELL SPECIFICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FATALITY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 80051677519     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.272     Document Type: Article

References (49)

1. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992-5001.
2. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44. (Pubitemid 40299772)
3. Svahn A, Berggren J, Parke A, Storsaeter J, Thorstensson R, Linde A. Changes in seroprevalence to four herpesviruses over 30 years in Swedish children aged 9-12 years. J Clin Virol 2006; 37: 118-123. (Pubitemid 44441977)
4. Takeuchi K, Tanaka-Taya K, Kazuyama Y, Ito YM, Hashimoto S, Fukayama M et al. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int 2006; 56: 112-116.
5. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107: 862-869. (Pubitemid 43156280)
6. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2009; 45: 385-391.
7. Chiang KY, Hazlett LJ, Godder KT, Abhyankar SH, Christiansen NP, van Rhee F et al. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1117-1123. (Pubitemid 34082966)
8. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
9. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
10. Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2009; 43: 315-321.
11. Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97-102. (Pubitemid 36850286)
12. Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekker AW, Verdonck LF. Increased incidence of EBV-associated lympho-proliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique. Bone Marrow Transplant 2002; 29: 335-339. (Pubitemid 34229039)
13. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
14. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproli-ferative disease in transplant recipients. Blood 2010; 115: 925-935.
15. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lym-phoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383-392.
16. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216. (Pubitemid 29467666)
17. Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76-84. (Pubitemid 38116876)
18. Guppy AE, Rawlings E, Madrigal JA, Amlot PL, Barber LD. A quantitative assay for Epstein-Barr virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat post-transplant lymphoproliferative disease. Transplantation 2007; 84: 1534-1539. (Pubitemid 350294730)
19. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297. (Pubitemid 36857791)
20. Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007; 13: 299-306.
21. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814-821. (Pubitemid 46902436)
22. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
23. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
24. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Harris NL, Stein H, Vardiman JW, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008, pp 343-349.
25. Gasser O, Bihl F, Sanghavi S, Rinaldo C, Rowe D, Hess C et al. Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation. Am J Transplant 2009; 9: 794-803.
26. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005; 174: 1037-1045. (Pubitemid 40094300)
27. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA et al. Epstein-Barr virus-associated posttrans-plantation lymphoproliferative disorder after high-dose im-munosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9: 583-591. (Pubitemid 38351790)
28. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-3389.
29. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113-116.
30. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-1505. (Pubitemid 30099868)
31. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576. (Pubitemid 43382145)
32. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112-118. (Pubitemid 32995103)
33. Frassoni F. Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation? Lancet Oncol 2009; 10: 839.
34. Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704-717.
35. Chen XH, Zhang C, Zhang X, Gao L, Kong PY, Peng XG et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 266-273.
36. Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 993-1003.
37. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008; 36: 1047-1054.
38. Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 913-919. (Pubitemid 351985029)
39. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573-584. (Pubitemid 43956362)
40. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
41. Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. High rabbit-anti-human thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lympho-proliferative disorder. Biol Blood Marrow Transplant 2010; 16: 915-926.
42. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008; 15: 576-585.
43. Omar H, Hagglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 2009; 11: 393-399.
44. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369. (Pubitemid 34627202)
45. Swinnen LJ. Immune-cell treatment of Epstein-Barr-virus-associated lymphoproliferative disorders. Best Pract Res Clin Haematol 2006; 19: 839-847. (Pubitemid 44418028)
46. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981. (Pubitemid 38596322)
47. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757-770.
48. Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 471-482.
49. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587-617. (Pubitemid 46697918)